How Is Emyria Scaling Perth Clinics to Drive National Mental Health Growth?
Emyria Limited is scaling up its Perth Empax clinic with increased therapist approvals and treatment rooms, setting the stage for broader national clinical growth next year.
- Perth clinic expands to four treatment rooms with increased weekly capacity
- Authorised psychiatrist approvals in Perth rise from 2 to 5, with more applications pending
- Therapist workforce grows to 39 trained and contracted professionals
- 67 initial patient screenings booked for Q1 2026, indicating strong demand
- Brisbane clinic progresses with first reimbursed patients nearing treatment completion
Scaling Clinical Capacity in Perth
Emyria Limited (ASX – EMD) has announced significant operational progress at its Perth Empax clinic, marking a pivotal step in its national expansion strategy for 2026. The company has increased its authorised psychiatrist (AP) approvals from two to five, with five additional applications advancing through the assessment process. This growth in clinical authorisations is complemented by a substantial increase in therapist capacity, now totaling 39 trained and contracted professionals ready to deliver Emyria’s evidence-based care protocols.
Physical capacity at the Perth clinic is also on the rise, with a third treatment room already operational and a fourth room approved and undergoing final fit-out. This expansion is expected to come online early in the first quarter of 2026, enabling higher patient throughput and supporting a larger cohort of individuals seeking reimbursed mental health treatments.
Strong Forward Patient Pipeline and Reimbursement Pathways
Forward bookings provide clear visibility into early 2026 activity, with 67 initial patient screenings already scheduled for the first quarter. These appointments span multiple reimbursement pathways, including insurance-funded programs and newly established Department of Veterans’ Affairs (DVA) access routes, which open treatment opportunities for veteran cohorts at Emyria’s West Leederville community clinic.
The company’s integration of private hospital infrastructure alongside community clinics offers a capital-efficient and scalable model. This approach not only accelerates commissioning timelines but also leverages emerging funders like the DVA to increase clinic utilisation.
Brisbane Clinic Progress Validates National Rollout
Meanwhile, Emyria’s Brisbane Empax clinic is nearing the completion of active treatment for its first three reimbursed patients. This milestone validates the company’s clinician recruitment, training, and clinical oversight models, setting a solid foundation for steady-state patient volumes throughout 2026. The Brisbane clinic’s progress underscores the replicability of Emyria’s Perth operating blueprint across other Australian markets.
Outlook and Strategic Implications
Executive Chairman Greg Hutchinson emphasised the maturity and scalability of the Perth network, highlighting rising approvals, strengthened therapist cohorts, and a robust patient pipeline. He positioned Perth as a template for rapid East Coast activation, signalling Emyria’s readiness to deliver significant clinical and operational growth in the coming year.
While the company’s forward-looking statements carry typical clinical and regulatory risks, the tangible operational advancements and expanding reimbursement pathways provide a compelling narrative for investors and stakeholders watching the evolving landscape of psychedelic-assisted psychotherapy and mental health services in Australia.
Bottom Line?
Emyria’s Perth expansion sets a strong foundation for national growth, but execution and reimbursement dynamics in 2026 will be critical to watch.
Questions in the middle?
- How will the newly established DVA access pathways impact patient volumes and revenue?
- What is the timeline and expected scale for Empax clinic rollouts on the East Coast?
- How will regulatory and clinical risks associated with psychedelic-assisted therapies influence growth?
